Tolga Atilla Ceranoglu1,2,3, Janet Wozniak1,2,3, Ronna Fried1,2,3, Maribel Galdo1,2, Barbora Hoskova1,2, Melissa DeLeon Fong1,2, Joseph Biederman1,2,3, Gagan Joshi1,2,3. 1. 1 Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital , Boston, Massachusetts. 2. 2 Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital , Boston, Massachusetts. 3. 3 Department of Psychiatry, Harvard Medical School , Boston, Massachusetts.
Abstract
OBJECTIVES: Anxiety disorders (ADs) are commonly associated with high-functioning Autism Spectrum Disorder (HF-ASD) and often worsen with age. Buspirone is a commonly prescribed anxiolytic drug with a favorable tolerability profile that may offer potential benefits in anxiety management for patients with HF-ASD. This study examines inadequately explored tolerability and effectiveness of buspirone in treating ADs comorbid with high-functioning ASD. METHODS: A retrospective chart review of a 1-year period was conducted in psychiatrically referred population of HF-ASD youth with AD (age 8-17 years) who were treated with buspirone (N = 31). Information on the demographics and treatment history was recorded. Effectiveness was assessed through the Clinical Global Impressions Scale (CGI) severity (CGI-S) and improvement (CGI-I) scores noted by the treating clinician. RESULTS: A total of 31 patients were prescribed buspirone during the determined period, at a mean dose of 41.61 ± 24.10 mg for an average duration of 272 ± 125 days. Change in the CGI-S mean scores with treatment suggests an overall improvement in the severity of anxiety symptoms (MT1 = 4.9 ± 0.7; MT2 = 2.8 ± 0.87; p < 0.001). Significant improvement in anxiety symptoms (CGI-I ≤ 2) was observed in 58% and mild improvement (CGI-I = 3) in 29% of the HF-ASD patients who received buspirone treatment. Buspirone was well tolerated with no adverse events reported by the majority of participants, with the exception of two subjects who developed treatment emergent adverse events (activation and mood lability). CONCLUSIONS: Findings from this retrospective chart review suggest a promising role of buspirone in managing anxiety among youth with HF-ASD. Further research with prospective and randomized-controlled trials is necessary.
OBJECTIVES:Anxiety disorders (ADs) are commonly associated with high-functioning Autism Spectrum Disorder (HF-ASD) and often worsen with age. Buspirone is a commonly prescribed anxiolytic drug with a favorable tolerability profile that may offer potential benefits in anxiety management for patients with HF-ASD. This study examines inadequately explored tolerability and effectiveness of buspirone in treating ADs comorbid with high-functioning ASD. METHODS: A retrospective chart review of a 1-year period was conducted in psychiatrically referred population of HF-ASD youth with AD (age 8-17 years) who were treated with buspirone (N = 31). Information on the demographics and treatment history was recorded. Effectiveness was assessed through the Clinical Global Impressions Scale (CGI) severity (CGI-S) and improvement (CGI-I) scores noted by the treating clinician. RESULTS: A total of 31 patients were prescribed buspirone during the determined period, at a mean dose of 41.61 ± 24.10 mg for an average duration of 272 ± 125 days. Change in the CGI-S mean scores with treatment suggests an overall improvement in the severity of anxiety symptoms (MT1 = 4.9 ± 0.7; MT2 = 2.8 ± 0.87; p < 0.001). Significant improvement in anxiety symptoms (CGI-I ≤ 2) was observed in 58% and mild improvement (CGI-I = 3) in 29% of the HF-ASDpatients who received buspirone treatment. Buspirone was well tolerated with no adverse events reported by the majority of participants, with the exception of two subjects who developed treatment emergent adverse events (activation and mood lability). CONCLUSIONS: Findings from this retrospective chart review suggest a promising role of buspirone in managing anxiety among youth with HF-ASD. Further research with prospective and randomized-controlled trials is necessary.
Authors: Denis G Sukhodolsky; Lawrence Scahill; Kenneth D Gadow; L Eugene Arnold; Michael G Aman; Christopher J McDougle; James T McCracken; Elaine Tierney; Susan Williams White; Luc Lecavalier; Benedetto Vitiello Journal: J Abnorm Child Psychol Date: 2007-08-03
Authors: Stephen J Blumberg; Matthew D Bramlett; Michael D Kogan; Laura A Schieve; Jessica R Jones; Michael C Lu Journal: Natl Health Stat Report Date: 2013-03-20
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Diane C Chugani; Harry T Chugani; Max Wiznitzer; Sumit Parikh; Patricia A Evans; Robin L Hansen; Ruth Nass; James J Janisse; Pamela Dixon-Thomas; Michael Behen; Robert Rothermel; Jacqueline S Parker; Ajay Kumar; Otto Muzik; David J Edwards; Deborah Hirtz Journal: J Pediatr Date: 2015-12-30 Impact factor: 4.406
Authors: Jorieke Duvekot; Jan van der Ende; Frank C Verhulst; Kirstin Greaves-Lord Journal: J Child Psychol Psychiatry Date: 2017-10-27 Impact factor: 8.982
Authors: Jessica L Armstrong; Austen B Casey; Tanishka S Saraf; Munmun Mukherjee; Raymond G Booth; Clinton E Canal Journal: ACS Pharmacol Transl Sci Date: 2020-02-21
Authors: Christopher J McDougle; Robyn P Thom; Caitlin T Ravichandran; Michelle L Palumbo; Laura C Politte; Jennifer E Mullett; Christopher J Keary; Craig A Erickson; Kimberly A Stigler; Lauren Mathieu-Frasier; David J Posey Journal: Neuropsychopharmacology Date: 2022-03-03 Impact factor: 8.294